SCHEDULE 13G/A: Ikarian Capital and Neil Shahrestani Disclose 9.99% Stake in Traws Pharma, Including Warrants

Investment adviser Ikarian Capital, LLC and Neil Shahrestani have disclosed a combined beneficial ownership of 9.99% of Traws Pharma, Inc.'s common stock, including shares acquirable via warrants.

Summary

• Ikarian Capital, LLC and Neil Shahrestani (the "Reporting Persons") have jointly filed an amended Schedule 13G, disclosing their beneficial ownership in Traws Pharma, Inc.
• As of March 31, 2025, the Reporting Persons collectively beneficially own 589,502 shares of Traws Pharma, Inc. common stock.
• This ownership represents 9.99% of the Issuer's outstanding common stock.
• The total beneficial ownership includes 561,009 shares of common stock that may be acquired within 60 days through the exercise of warrants held by the Reporting Persons.
• The exercise of these warrants is subject to restrictions, preventing the Reporting Persons from exceeding 9.99% beneficial ownership upon conversion.
• The percentage of class is calculated based on 5,895,024 shares of common stock outstanding, which comprises the 561,009 warrant shares and 5,334,015 shares outstanding as of April 28, 2025, as reported in Traws Pharma's amended Form 10-K filed on April 30, 2025.
• Ikarian Capital, LLC is an investment adviser, and Neil Shahrestani indirectly controls Ikarian Capital, LLC.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing (Schedule 13G) disclosing beneficial ownership, which is generally neutral in sentiment. It provides factual information about a significant stake without indicating positive or negative operational performance or strategic shifts for the issuer.

Risks

• The exercise of warrants is subject to certain restrictions, specifically that the number of shares beneficially owned by the Reporting Persons would not exceed 9.99% of the outstanding shares of Common Stock upon conversion.

Future Outlook

NA

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

This filing is a routine disclosure of a significant ownership stake by an investment adviser and its principal, common in the financial industry for transparency regarding large holdings in publicly traded companies.

Stakeholder Impact

• Shareholders: The disclosure of a significant 9.99% stake by an investment adviser and its principal provides transparency regarding a large institutional holding, which could influence market perception and trading activity.

Key Dates

Keywords

Traws Pharma, Ikarian Capital, Neil Shahrestani, Schedule 13G, Beneficial Ownership, Common Stock, Warrants, Investment Adviser, SEC Filing